Clinical Trial Update: Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Phase 4]

View source ↗

Summary

Phase 4 trial updating preference attributes of ELLIPTA and HANDIHALER dry powder inhalers in COPD patients; results completed with posted results in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• ELLIPTA Dry Powder Inhaler
• HANDIHALER Dry Powder Inhaler

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 4 | Status: COMPLETED | Results posted: 2017-06-22